Long-term outcome in adults with obsessive-compulsive disorder

Depression and Anxiety

Volumn 30, Issue 8, 2013, Pages 716-722

  Bloch, Michael H ^a,b   Green, Christy ^a,b   Kichuk, Stephen A ^b   Dombrowski, Philip A ^a   Wasylink, Suzanne ^b   Billingslea, Eileen ^b   Landeros Weisenberger, Angeli ^a   Kelmendi, Benjamin ^b   Goodman, Wayne K ^c   Leckman, James F ^a,b   Coric, Vladimir ^b,d   Pittenger, Christopher ^a,b,e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e YALE UNIVERSITY   (United States)

Author keywords

anxiety anxiety disorders; OCD obsessive compulsive disorder; pharmacotherapy; treatment; treatment resistance

Indexed keywords

PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); DISEASE DURATION; DISEASE SEVERITY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OBSESSIVE COMPULSIVE DISORDER; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; REMISSION; TREATMENT RESPONSE;

ANXIETY/ANXIETY DISORDERS; OCD/OBSESSIVE COMPULSIVE DISORDER; PHARMACOTHERAPY; TREATMENT; TREATMENT RESISTANCE;

ADULT; ANTIPSYCHOTIC AGENTS; COGNITIVE THERAPY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84881478288     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22103     Document Type: Article

References (43)

1. Karno M, Golding JM, Sorenson SB, Burnam M,. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 1988; 45: 1094-1099.
2. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8-19.
3. Rasmussen SA, Eisen JL,. The epidemiology and differential diagnosis of obsessive compulsive disorder. J Clin Psychiatry 1994; 55 (Suppl): 5-10; discussion 11-4.
4. Sasson Y, Zohar J, Chopra M, et al. Epidemiology of obsessive-compulsive disorder: a world view. J Clin Psychiatry 1997; 58 (Suppl 12): 7-10.
5. Ruscio AM, Stein DJ, Chiu WT, Kessler RC,. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 2010; 15: 53-63.
6. Koran LM, Thienemann ML, Davenport R,. Quality of life for patients with obsessive-compulsive disorder. Am J Psychiatry 1996; 153: 783-788.
7. Skoog G, Skoog I,. A 40-year follow-up of patients with obsessive-compulsive disorder [see commetns]. Arch Gen Psychiatry 1999; 56: 121-127.
8. Berrios GE, Chiu H,. Obsessive-compulsive disorders in Cambridgeshire. A follow-up study of up to 20 years. Br J Psychiatry Suppl 1989; 4: 17-20.
9. Delkeskamp H., [Long-term catamnesis of obsessive-compulsive neuroses]. Acta Psychiatrica Scandinavica 1965; 41: 564-581.
10. Kringlen E,. Obsessional neurotics: a long-term follow-up. Br J Psychiatry 1965; 111: 709-722.
11. Muller C., [Preliminary report on the lengthy catamnesis of obsessive disorders]. Der Nervenarzt 1953; 24: 112-115.
12. Rudin E., [On the problem of compulsive disease with special reference to its hereditary relations]. Archiv fur Psychiatrie und Nervenkrankheiten, vereinigt mit Zeitschrift fur die gesamte Neurologie und Psychiatrie 1953; 191: 14-54.
13. Goodwin DW, Guze SB, Robins E,. Follow-up studies in obsessional neurosis. Arch Gen Psychiatry 1969; 20: 182-187.
14. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown obsessive compulsive scale. II. validity. Arch Gen Psychiatry 1989; 46: 1012-1016.
15. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown obsessive compulsive scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46: 1006-1011.
16. Pallanti S, Hollander E, Bienstock C, et al. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 2002; 5: 181-191.
17. van Oppen P, van Balkom AJ, de Haan E, van Dyck R,. Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up. J Clin Psychiatry 2005; 66: 1415-1422.
18. Steketee G, Eisen J, Dyck I, et al. Predictors of course in obsessive-compulsive disorder. Psychiatry Res 1999; 89: 229-238.
19. Stewart SE, Geller DA, Jenike M, et al. Long-term outcome of pediatric obsessive-compulsive disorder: a meta-analysis and qualitative review of the literature. Acta Psychiatrica Scandinavica 2004; 110: 4-13.
20. Landeros-Weisenberger A, Bloch MH, Kelmendi B, et al. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder. J Affective Disord 2010; 121: 175-179.
21. Goodman WK, Kozak MJ, Liebowitz M, White KL,. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 1996; 11: 21-29.
22. Goodman WK, Price LH, Rasmussen SA, et al. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry 1989; 46: 36-44.
23. Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group. Arch Gen Psychiatry 1991; 48: 730-738.
24. Bloch MH, Landeros-Weisenberger A, Rosario MC, et al. Meta-analysis of the symptom structure of obsessive-compulsive disorder. Am J Psychiatry 2008; 165: 1532-1542.
25. Guy W, Cleary PA,. Pretreatment status and its relationship to the length of drying-out period. Psychopharmacol Bull 1976; 12: 20-22.
26. Hamilton M,. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50-55.
27. Hamilton M, White JM,. Clinical syndromes in depressive states. J Mental Sci 1959; 105: 985-998.
28. Eisen JL, Pinto A, Mancebo MC, et al. A 2-year prospective follow-up study of the course of obsessive-compulsive disorder. J Clin Psychiatry 2010; 71: 1033-1039.
29. Arnold PD, Sicard T, Burroughs E, et al. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry 2006; 63: 769-776.
30. Pittenger C, Krystal JH, Coric V,. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 2006; 3: 69-81.
31. Rosenberg DR, MacMaster FP, Keshavan MS, et al. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 2000; 39: 1096-1103.
32. Rosenberg DR, MacMillan SN, Moore GJ,. Brain anatomy and chemistry may predict treatment response in paediatric obsessive-compulsive disorder. Int J Neuropsychopharmacol 2001; 4: 179-190.
33. Whiteside SP, Port JD, Deacon BJ, Abramowitz JS,. A magnetic resonance spectroscopy investigation of obsessive-compulsive disorder and anxiety. Psychiatry Res 2006; 146 (2): 137-147.
34. Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S,. Glutamatergic dysfunction in OCD. Neuropsychopharmacology 2005; 30: 1735-1740.
35. Stewart SE, Fagerness JA, Platko J, et al. Association of the SLC1A1 glutamate transporter gene and obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet 2007; 144: 1027-1033.
36. Dickel DE, Veenstra-VanderWeele J, Cox NJ, et al. Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Arch Gen Psychiatry 2006; 63: 778-785.
37. Coric V, Taskiran S, Pittenger C, et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 2005; 58: 424-428.
38. Lafleur DL, Pittenger C, Kelmendi B, et al. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl) 2006; 184: 254-256.
39. Poyurovsky M, Weizman R, Weizman A, Koran L,. Memantine for treatment-resistant OCD. Am J Psychiatry 2005; 162: 2191-2192.
40. Pasquini M, Biondi M,. Memantine augmentation for refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1173-1135.
41. Berlin HA, Koran LM, Jenike MA, et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2011; 72: 716-721.
42. Bruno A, Mico U, Pandolfo G, et al. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol 2012; 26: 1456-1462.
43. Greenberg BD, Rauch SL, Haber SN,. Invasive circuitry-based neurotherapeutics: stereotactic ablation and deep brain stimulation for OCD. Neuropsychopharmacology 2010; 35: 317-336.